To date, FDA has approved in total 3 siRNA-based drugs since 2017. According to official sources Patisiran (Onpattro) - the first siRNA-based therapeutic approved by FDA, costs over $450,000 per patient per year. The average annual cost of the second FDA-approved siRNA-based drug Givosiran (Gilvaari) is approximately $575,000. Meanwhile the third, and last (up till now) approved siRNA drug Lumasiran (Oxlumo) costs over $490,000.
Easy answer! First, it's got nothing to do with R&D, innovation or manufacturing costs. Those are all lies.
The United States exports the vicious notion that intellectual property "rights" must be preserved even though the result is market-driven research that is antithetical to science, medicine and humanity and is perverted into justifying outrageous, capricious, arbitrary and cruel pricing strategies. This comes from enormously powerful, vicious and vindictive executives who control politicians in the US, EU and elsewhere and the US Trade Representative, a cruel lapdog to industry who threatens any LMIC trying to get less costly interventions. The result is prolonged pandemic, millions suffering and dying needlessly not just from covid but HIV, hep C, TB, malaria, diabetes, malnutrition all to pay off the horrific ransom demands on our lives to the benefit of said executives and their parasitic shareholders. The result of this fiscal rape is a form of economic genocide. Clear enough?
George Carter Thank you for your answer. I got the point. However, on the other hand, all these drugs approved for marketing are designed to treat rare hereditary diseases. Therefore, It is also rational to explain the high cost of these drugs with the rareness of the particular diseases. Interestingly, one of siRNA drugs called inclisiran (ALN-PCSSC) that is in phase 3 trial is designed for wider population as it treats hypercholesterolemie (via targeting LDL-C key protein called PCSK9). I certainly wonder how much the drug will cost in case of approval.
Actually, you'll need to provide evidence to persuade me. The costs of clinical trials, even phase 3, are nothing like what pharma claims. Let alone the market-driven approach to discovery often results in faulty trial designs that are more marketing tools than actual science, interfering dangerously with the practice of medicine. Rare diseases, hereditary or not, are very often largely publicly funded from bench almost all the way to bedside. The capital contribution of companies dwindles as their ransom demands absurdly and horrifically increase. And more people around the world suffer and die because of their greed.
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Pharmaceuticals
- Drugs